Search Results
Jul 31, 2026, 03:57 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with SBS Law
statements to the market. Grail misled investors about the prospects of its NHS-Galleri trial in reducing Stage III-IV cancers, concealing adverse facts from the trial while describing it positively. The Company's optimism related to the NHS-Galleri study was overstated, and ignored data suggesting its three-year
More news about: Schall, Brown & Schwartz LLP
Jul 31, 2026, 02:47 ET GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL
August 4, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Grail described its NHS-Galleri trial in positive terms while concealing adverse facts about the trial's results. Based on these facts, Grail's public statements were false
More news about: DJS Law Group LLP
Jul 30, 2026, 14:45 ET Proteotype Launches €3 Million European Study to Advance Multi-Cancer Detection and Evaluate Home Blood Collection
MODERNISED study, which is evaluating 10 cancer types in real-world NHS settings, INNOVATOR will extend the programme to 12 cancer types in Portugal, Spain and Germany. It will recruit 2,000 participants: approximately 1,200
More news about: Proteotype Diagnostics
Jul 30, 2026, 14:07 ET Proteotype Launches €3 Million European Study to Advance Multi-Cancer Detection and Evaluate Home Blood Collection
MODERNISED study, which is evaluating 10 cancer types in real-world NHS settings, INNOVATOR will extend the programme to 12 cancer types in Portugal, Spain and Germany. It will recruit 2,000 participants: approximately 1,200
More news about: Proteotype Diagnostics
Jul 30, 2026, 10:07 ET SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL
Wall Street's Reassessment of Grail: How Analyst Expectations Built on Positive NHS-Galleri Representations Collapsed Alongside GRAL's $51.32 Per-Share DeclineNEW YORK, July 30, 2026 /PRNewswire/ -- SueWallSt
More news about: SueWallSt.com
Jul 29, 2026, 21:19 ET Innova NanoJet Wins UK Enterprise Awards 2026 for Water-Based, Filter-Free Air Purification
NanoJet® technology cleared 93% of airborne bacteria in 10 minutes in NHS-linked laboratory testing using only water — and is one of only two suppliers named to both the disinfection-machine and air-purification lots of the new NHS Supply Chain framework.GLASGOW,
More news about: Pasaca Capital Inc.
Jul 29, 2026, 20:54 ET Innova NanoJet Wins UK Enterprise Awards 2026 for Water-Based, Filter-Free Air Purification
NanoJet® technology cleared 93% of airborne bacteria in 10 minutes in NHS-linked laboratory testing using only water — and is one of only two suppliers named to both the disinfection-machine and air-purification lots of the new NHS Supply Chain framework.GLASGOW,
More news about: Pasaca Capital Inc.
Jul 29, 2026, 13:21 ET GRAL INVESTOR ALERT: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- Hagens Berman
Claims: The lawsuit contends that GRAIL and certain senior executives misled investors regarding the clinical design, progress, and efficacy of its landmark NHS-Galleri cancer screening trial. Defendants repeatedly asserted that the study was optimally structured with a three-year follow-up period to demonstrate
More news about: Hagens Berman Sobol Shapiro LLP
Jul 29, 2026, 11:17 ET HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline
Claims: The lawsuit contends that GRAIL and certain senior executives misled investors regarding the clinical design, progress, and efficacy of its landmark NHS-Galleri cancer screening trial. Defendants repeatedly asserted that the study was optimally structured with a three-year follow-up period to demonstrate
More news about: Hagens Berman Sobol Shapiro LLP
Jul 29, 2026, 10:09 ET Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL
after Grail disclosed the NHS-Galleri trial failed to achieve its primary endpoint. The lead plaintiff deadline is August 4, 2026.What They Allegedly KnewThe securities action contends that Grail's leadership possessed internal data from the NHS-Galleri prevalent screening
More news about: Levi & Korsinsky, LLP
Jul 29, 2026, 10:01 ET Biopsy Devices Market to Reach US$ 11.2 Bn by 2033 Advances with AI-Driven Precision Diagnostics - Persistence Market Research
regional revenues due to high healthcare expenditure and sophisticated hospital infrastructure, while the United Kingdom continues expanding through NHS-led early diagnosis initiatives. Latin America and the Middle East are also witnessing gradual market expansion as healthcare investments improve access
More news about: Persistence Market Research Pvt. Ltd.
Jul 28, 2026, 18:51 ET GRAL Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: THE ROSEN LAW FIRM, P. A.
Jul 28, 2026, 12:21 ET GRAIL, Inc. (NASDAQ: GRAL) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
for more than 50 cancer types through a single blood draw.The complaint alleges that Defendants failed to disclose that: (i) the NHS-Galleri trial, as structured and executed within its three-year follow-up period, was insufficient to demonstrate whether GRAIL's primary endpoint —
More news about: Berger Montague
Jul 28, 2026, 10:10 ET HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline
Claims: The lawsuit contends that GRAIL and certain senior executives misled investors regarding the clinical design, progress, and efficacy of its landmark NHS-Galleri cancer screening trial. Defendants repeatedly asserted that the study was optimally structured with a three-year follow-up period to demonstrate
More news about: Hagens Berman Sobol Shapiro LLP
Jul 28, 2026, 10:07 ET Lost Money on GRAIL, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: The Gross Law Firm
Jul 28, 2026, 06:36 ET GRAL Class Reminder: GRAIL, Inc. Investors are Reminded of the Upcoming August 4 Deadline in the Filed Securities Fraud Class Action to Recover Losses
implementation of its test as a national screening program through the United Kingdom's National Health Service ("NHS"), GRAIL conducted the "NHS-Galleri trial." The primary objective of the NHS-Galleri trial was "to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test
More news about: Bleichmar Fonti & Auld LLP
Jul 28, 2026, 04:08 ET GRAIL, Inc. Investor Alert: Contact SBS by August 4, 2026 for Opportunity to Lead Securities Fraud Lawsuit
statements to the market. Grail misled investors about the prospects of its NHS-Galleri trial in reducing Stage III-IV cancers, concealing adverse facts from the trial while describing it positively. The Company's optimism related to the NHS-Galleri study was overstated, and ignored data suggesting its three-year
More news about: Schall, Brown & Schwartz LLP
Jul 27, 2026, 09:30 ET GRAL INVESTOR ALERT: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- HBSS
Claims: The lawsuit contends that GRAIL and certain senior executives misled investors regarding the clinical design, progress, and efficacy of its landmark NHS-Galleri cancer screening trial. Defendants repeatedly asserted that the study was optimally structured with a three-year follow-up period to demonstrate
More news about: Hagens Berman Sobol Shapiro LLP
Jul 27, 2026, 04:37 ET GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL
August 4, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Grail described its NHS-Galleri trial in positive terms while concealing adverse facts about the trial's results. Based on these facts, Grail's public statements were false
More news about: DJS Law Group LLP
Jul 24, 2026, 16:45 ET INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Grail Class Action Lawsuit
significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial, while also concealing material adverse facts which reduced the possibility of such an outcome; (ii) in truth, Grail's optimism in achieving the primary endpoint of its NHS-Galleri study fell short of reality; and (iii) the confidence
More news about: Robbins Geller Rudman & Dowd LLP
Jul 24, 2026, 08:00 ET HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline
Claims: The lawsuit contends that GRAIL and certain senior executives misled investors regarding the clinical design, progress, and efficacy of its landmark NHS-Galleri cancer screening trial. Defendants repeatedly asserted that the study was optimally structured with a three-year follow-up period to demonstrate
More news about: Hagens Berman Sobol Shapiro LLP
Jul 23, 2026, 18:12 ET GRAIL, Inc. Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: THE ROSEN LAW FIRM, P. A.
Jul 23, 2026, 10:09 ET Lost Money on Grail, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
disclosed its NHS-Galleri trial failed to achieve its primary endpoint. Investors have until August 4, 2026 to seek lead plaintiff appointment.The Early OptimismIn May 2025, Grail announced positive top-line results from the prevalent screening round of its 140,000-participant NHS-Galleri
More news about: SueWallSt.com
Jul 23, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines - GRAL
action] On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately." On
More news about: Pomerantz LLP
Jul 23, 2026, 09:00 ET GRAL INVESTOR ALERT: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- HBSS
laws by GRAIL, Inc. (NASDAQ: GRAL). The suit contends the company misled investors regarding the clinical design and efficacy of its landmark NHS-Galleri cancer screening trial.
More news about: Hagens Berman Sobol Shapiro LLP